Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: Balance between diabetogenic effects and inflammation reduction

Arthritis and Rheumatism

Volumn 64, Issue 3, 2012, Pages 639-646

  Den Uyl, Debby ^a   Van Raalte, Daniel H ^a   Nurmohamed, Michael T ^a   Lems, Willem F ^a   Bijlsma, Johannes W J ^b   Hoes, Jos N ^b   Dijkmans, Ben A C ^a   Diamant, Michaela ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; PREDNISOLONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK; SINGLE BLIND PROCEDURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; FEMALE; GLUCOCORTICOIDS; GLUCOSE TOLERANCE TEST; HEALTH STATUS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; JOINTS; MALE; MIDDLE AGED; PREDNISOLONE; SEVERITY OF ILLNESS INDEX;

EID: 84857694532     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33378     Document Type: Article

References (38)

1. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61: 1571-9.
2. Wasko MC, Kay J, Hsia EC, Rahman MU,. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken) 2011; 63: 512-21.
3. Weyer C, Bogardus C, Mott DM, Pratley RE,. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94.
4. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008; 58: 2105-12.
5. Dessein PH, Joffe BI,. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2765-75.
6. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1010-4.
7. Van Raalte DH, Ouwens DM, Diamant M,. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93.
8. Van Raalte DH, Nofrate V, Bunck MC, van Iersel T, Elassaiss Schapp J, Nassander UK, et al. Acute and 2-week exposure to prednisolone impair different aspects of β-cell function in healthy men. Eur J Endocrinol 2010; 162: 729-35.
9. Gulliford MC, Charlton J, Latinovic R,. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006; 29: 2728-9.
10. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J,. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154: 97-101.
11. Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M,. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004; 31: 867-74.
12. Van Tuyl LH, Boers M, Lems WF, Landewe RB, Han H, van der Linden S, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010; 69: 807-12.
13. Wolfe F, Michaud K,. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004; 31: 695-700.
14. Hallgren R, Berne C,. Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med Scand 1983; 213: 351-5.
15. Svenson KL, Lundqvist G, Wide L, Hallgren R,. Impaired glucose handling in active rheumatoid arthritis: effects of corticosteroids and antirheumatic treatment. Metabolism 1987; 36: 944-8.
16. Wallace TM, Levy JC, Matthews DR,. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
18. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston: Little Brown; 1994. p. 253-6.
19. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
20. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
21. Kotronen A, Vehkavaara S, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H,. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 2007; 293: E1709-15.
22. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-6.
23. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34 Suppl 1: S11-61.
24. Mari A, Ferrannini E,. Beta-cell function assessment from modelling of oral tests: an effective approach. Diabetes Obes Metab 2008; 10 Suppl 4: 77-87.
25. Levy JC, Matthews DR, Hermans MP,. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191-2.
26. Van Tuyl LH, Plass AM, Lems WF, Voskuyl AE, Dijkmans BA, Boers M,. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? Ann Rheum Dis 2007; 66: 974-6.
27. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39: 298-305.
28. Svenson KL, Lundqvist G, Wide L, Hallgren R,. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 1987; 36: 940-3.
29. Hotamisligil GS,. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
30. Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M,. Insulin resistance associated to obesity: the link TNF-α. Arch Physiol Biochem 2008; 114: 183-94.
31. Xi L, Xiao C, Bandsma RH, Naples M, Adeli K, Lewis GF,. C-reactive protein impairs hepatic insulin sensitivity and insulin signaling in rats: role of mitogen-activated protein kinases. Hepatology 2011; 53: 127-35.
32. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA,. Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24: 325-31.
33. Gurzov EN, Germano CM, Cunha DA, Ortis F, Vanderwinden JM, Marchetti P, et al. p53 up-regulated modulator of apoptosis (PUMA) activation contributes to pancreatic β-cell apoptosis induced by proinflammatory cytokines and endoplasmic reticulum stress. J Biol Chem 2010; 285: 19910-20.
34. Owens DR, Wragg KG, Biggs PI, Luzio S, Davies CJ, Jones MK,. The reproducibility of serial meal and oral glucose tolerance tests in normal subjects. Diabetes Metab 1981; 7: 25-33.
35. Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004; 50: 2423-7.
36. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003; 48: 46-53.
37. Van Rossum EF, Lamberts SW,. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 2004; 59: 333-57.
38. Buttgereit F, Da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002; 61: 718-22.